Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06274528
PHASE2

DORA and LP in Alzheimer's Disease Biomarkers

Sponsor: Washington University School of Medicine

View on ClinicalTrials.gov

Summary

The purpose of this study is to see if the sleep aid, lemborexant, can decrease the amount of amyloid-beta and tau in the blood. Amyloid-beta and tau are proteins involved in the disease process leading to Alzheimer's disease.

Official title: Effect of a Dual Orexin Receptor Antagonist on CSF Alzheimer's Disease Biomarkers

Key Details

Gender

All

Age Range

65 Years - Any

Study Type

INTERVENTIONAL

Enrollment

201

Start Date

2024-03-11

Completion Date

2029-03-11

Last Updated

2025-11-05

Healthy Volunteers

Yes

Interventions

DRUG

Lemborexant 10 mg

Within FDA approved dose 10 mg; capsule; QD, 6 month duration

DRUG

Lemborexant 20mg

20 mg; capsule; QD; 6 month duration

DRUG

Placebo

0 mg; capsule; QD; 6 month duration

Locations (1)

Washington University in St. Louis, School of Medicine

St Louis, Missouri, United States